Journal of Gastric Cancer

  • 제9권4호
  • /
  • Pages.269-274
  • /
  • 2009
  • /
  • 2093-582X(pISSN)
  • /
  • 2093-5641(eISSN)
대한위암학회 (The Korean Gastric Cancer Association)
권호 표지

수술 전 항암요법이 절제 불가능한 위암 환자의 수술에 미치는 영향

The Impact of Preoperative Chemotherapy on the Surgical Management of Unresectable Gastric Cancer

  • 윤삼열 (울산대학교 의과대학 외과학교실, 상부위장관 외과) ;
  • 김민규 (울산대학교 의과대학 외과학교실, 상부위장관 외과) ;
  • 오성태 (울산대학교 의과대학 외과학교실, 상부위장관 외과)
  • Yoon, Sam-Youl (Division of Gastric Surgery, Department of Surgery, University of Ulsan College of Medicine) ;
  • Kim, Min-Gyu (Division of Gastric Surgery, Department of Surgery, University of Ulsan College of Medicine) ;
  • Oh, Sung-Tae (Division of Gastric Surgery, Department of Surgery, University of Ulsan College of Medicine)
  • 투고 : 2009.09.14
  • 심사 : 2009.10.30
  • 발행 : 2009.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 최근들어 근치적 절제가 어려운 위암을 대상으로 수술 전 항암요법(preoperative chemotherapy)이 병기를 낮추어 완전 절제율을 높일 수 있다는 연구가 보고되고 있으나, 항암요법이 수술에 미치는 영향에 대한 연구가 부족하여 본원의 경험을 조사하고자 하였다. 대상 및 방법: 2001년 12월부터 2009년 1월까지 동일한 항암요법을 시행 받은 후 위 절제술을 시행한 46명을 대상으로 수술 전 전신 상태, 수술 소견 및 수술 후 임상 경과등을 분석하였다. 결과: 항암요법은 평균 4.4회가 시행되었고, 각각 4명의 환자들에서 절대 호중구 수치(absolute neutrophil count)가 1,500(${\mu}/L$) 이하로 떨어지거나 10% 이상의 체중 감소를 보였다. 29명은 수술 중 종양과 주위 장기와의 유착 또는 단단하게 고정된 소견을 보였으며, 근치적 목적의 병할 절제를 시행한 13명의 환자 중 4명만이 병리학적으로 타 장기 침범이 관찰 되었다. 근치적 위 절제술은 41명, 수술 후 합병증은 10명에서 발생하였으며, 수술 후 60일 내 사망은 없었다. 결론: 항암요법이 수술 전 환자에 미치는 영향은 적을 것으로 생각되며, 타 장기 침범 소견으로 병합절제를 시행한 상당수에서 종양이 없었던 것은 일부 항암 효과가 작용한 것으로 생각한다. 더불어 항암 요법 자체가 수술 후 합병증 발생률을 높이는 것으로 생각되지 않는다.

Purpose: There have been reported that preoperative chemotherapy for treating noncurative gastric cancer could increase the R0 resection rate by downstaging the gastric cancer. Yet there have been only rare reports about the effect of preoperative chemotherapy on performing surgery for noncurative gastric cancer. Our study was designed to analyze our experiences with these effects. Materials and Methods: We retrospectively analyzed 46 patients who had undergone gastrectomy after chemotherapy between December 2001 and January 2009. The patients' preoperative condition, the operative findings and the postoperative clinical coursed were analyzed. Results: Preoperative chemotherapy was performed for a mean of 4.4 cycles. Four patients showed a level of ANC below 1,500 (${\mu}/L$) and above a 10 percentile weight loss, respectively. For an operation, we found fibrosis or fixation between the tumor and the adjacent organs in 29 patients, and 4 of the 13 patients who underwent resection with another organ were documented to have invasion by tumor. Forty one patients underwent curative resection. Ten patients developed postoperative complications. There was no mortality at postoperative 60 days. Conclusion: We assumed that preoperative chemotherapy had little effect on the patient preoperatively, and it had some effect on down-staging pathologically. Preoperative chemotherapy didn't increase the postoperative complication rate.

키워드

참고문헌

  1. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999;17:2403-2411. https://doi.org/10.1200/JCO.1999.17.8.2403
  2. Korean Gastric Cancer Association. Nationwide gastric cancer report in Korea. J Korean Gastric Cancer Assoc 2002;2:105-114. https://doi.org/10.5230/jkgca.2002.2.2.105
  3. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopatholgic characteristics and prognostic factors in 10,783 patients with gastric cancer. Gastric Cancer 1998;1:125-133. https://doi.org/10.1007/s101200050006
  4. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002;168:597-608. https://doi.org/10.1080/11024150201680005
  5. Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous metaanalyses. Tumori 2002;88:21-27.
  6. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-1530. https://doi.org/10.1002/cncr.11660
  7. Park SR. Preoperative chemotherapy in advanced stomach cancer (Pros). J Korean Gastric Cancer Assoc 2008;8:57-64. https://doi.org/10.5230/jkgca.2008.8.2.57
  8. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989;7:1318-1326. https://doi.org/10.1200/JCO.1989.7.9.1318
  9. Oh S. Preoperative Chermotherapy in Advanced Stomach Cancer (Cons). J Korean Gastric Cancer Assoc 2008;8:65-69. https://doi.org/10.5230/jkgca.2008.8.2.65
  10. Therasse P, Arbuck SG, Eisenhauer EA, Wander J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst 2000;92:205-216. https://doi.org/10.1093/jnci/92.3.205
  11. De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M. Neoadjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007;18(Suppl 6):120-123.
  12. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH; Cooperating Investigators of The Dutch Gastric Cancer Group. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30:643-649. https://doi.org/10.1016/j.ejso.2004.04.013
  13. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  14. Byun GY, Park JM, Kim HI, Kim JH, Park SS, Kim SJ, Mok YJ, Kim CS. Clinicopathological features and prognostic factors for patients with clinical T4 gastric cancer that underwent combined resection of invaded organs. J Korean Gastric Cancer Assoc 2007;7:117-123. https://doi.org/10.5230/jkgca.2007.7.3.117
  15. Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005;92:1099-1102. https://doi.org/10.1002/bjs.4952
  16. Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A; Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 2005;92:1103-1109. https://doi.org/10.1002/bjs.4979